Table 1.
Systemic sclerosis (n = 19) | |
---|---|
Age, (years) |
55.2 ± 10.8 |
Sex (female), [n (%)] |
13 (68.4%) |
Disease duration, (years) |
60 ± 4.5 |
Time of follow-up examination after baseline examination, (days) |
756.6 ± 8.8 |
Time of baseline echocardiography between right heart catheter, (days) |
6.0 ± 10.4 |
Body mass index (kg/m2) |
24.0 ± 2.7 |
Arterial hypertension, [n (%)] |
4 (21.1) |
Smoker, [n (%)] |
2 (10.5) |
Raynaud’s syndrom, [n (%)] |
8 (42.1) |
Modified Rodnan Skin Score |
8.2 ± 6.5 |
Anti-centromere antibodies, [n (%)] |
4 (21.1) |
Anti-Scl-70 antibodies, [n (%)] |
7 (36.8) |
Pulmonary fibrosis, [n (%)] |
8 (42.1) |
Impaired renal function, [n (%)] |
2 (10.5) |
Invasive measurements
| |
Cardiac output, (l/min) |
5.4 ± 0.7 |
Cardiac index, (l/min/m2) |
3.0 ± 0.4 |
PAP systolic, (mmHg) |
27.3 ± 4.9 |
PAP diastolic, (mmHg) |
11.2 ± 3.1 |
PAP mean, (mmHg) |
17.7 ± 3.5 |
PCWP mean, (mmHg) |
10.1 ± 3.6 |
SVR, (dyn × sec × cm-5) |
2203.3 ± 787.7 |
PVR, (dyn × sec × cm-5) | 188.3 ± 98.6 |
Data are expressed as mean ± SD, except gender, hypertension, and except disease duration and time of follow-up examination, which are expressed as median ± SD. SSc, systemic sclerosis; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; SVR, systemic vascular resistance; PVR, pulmonary vascular resistance.